Cargando…

Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer

BACKGROUND: The TMPRSS2-ERG gene fusion resulting in ERG overexpression has been found in around 50% of prostate cancers (PCa) and is a very early event in tumorigenesis. Most studies have reported on selected surgical cohorts with inconsistent results. We hypothesized that ERG gene rearrangements i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schaefer, G, Mosquera, J-M, Ramoner, R, Park, K, Romanel, A, Steiner, E, Horninger, W, Bektic, J, Ladurner-Rennau, M, Rubin, M A, Demichelis, F, Klocker, H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3655380/ https://www.ncbi.nlm.nih.gov/pubmed/23381693 http://dx.doi.org/10.1038/pcan.2013.4

Ejemplares similares

Age-Adjusted PSA Levels in Prostate Cancer Prediction: Updated Results of the Tyrol Prostate Cancer Early Detection Program
por: Heidegger, Isabel, et al.
Publicado: (2015)

High Risk of Under-Grading and -Staging in Prostate Cancer Patients Eligible for Active Surveillance
por: Heidegger, Isabel, et al.
Publicado: (2015)

Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response
por: Kafka, Mona, et al.
Publicado: (2022)

Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008
por: Oberaigner, Willi, et al.
Publicado: (2011)

Novel therapeutic approaches for the treatment of castration-resistant prostate cancer()
por: Heidegger, Isabel, et al.
Publicado: (2013)

ERG Rearrangement Is Associated with Prostate Cancer-Related Death in Chinese Prostate Cancer Patients
por: Qi, Mei, et al.
Publicado: (2014)

Validation of Cell-Free RNA and Circulating Tumor Cells for Molecular Marker Analysis in Metastatic Prostate Cancer
por: Ladurner, Michael, et al.
Publicado: (2021)

Past, Current, and Future Strategies to Target ERG Fusion-Positive Prostate Cancer
por: Lorenzin, Francesca, et al.
Publicado: (2022)

Molecular Composition of Genomic TMPRSS2-ERG Rearrangements in Prostate Cancer
por: Krumbholz, Manuela, et al.
Publicado: (2019)

Characterization of Transcriptional Changes in ERG Rearrangement-Positive Prostate Cancer Identifies the Regulation of Metabolic Sensors Such as Neuropeptide Y
por: Massoner, Petra, et al.
Publicado: (2013)

High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer
por: Heumann, Asmus, et al.
Publicado: (2018)

Insulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancer
por: Massoner, P, et al.
Publicado: (2010)

Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers
por: Burdelski, Christoph, et al.
Publicado: (2015)

ERG induces taxane resistance in castration-resistant prostate cancer
por: Galletti, Giuseppe, et al.
Publicado: (2014)

ERG Induces Epigenetic Activation of Tudor Domain-Containing Protein 1 (TDRD1) in ERG Rearrangement-Positive Prostate Cancer
por: Kacprzyk, Lukasz A., et al.
Publicado: (2013)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

The Use of Dietary Supplements to Alleviate Androgen Deprivation Therapy Side Effects during Prostate Cancer Treatment
por: Dueregger, Andrea, et al.
Publicado: (2014)

Antidiabetic drugs influence molecular mechanisms in prostate cancer
por: Pircher, Andreas, et al.
Publicado: (2018)

Testing mutual exclusivity of ETS rearranged prostate cancer
por: Svensson, Maria A, et al.
Publicado: (2011)

Benefits and harms of prostate cancer screening – predictions of the ONCOTYROL prostate cancer outcome and policy model
por: Mühlberger, Nikolai, et al.
Publicado: (2017)

Real-Time Elastography of the Prostate
por: Junker, D., et al.
Publicado: (2014)

Robo 4 - the double-edged sword in prostate cancer: impact on cancer cell aggressiveness and tumor vasculature
por: Pircher, Andreas, et al.
Publicado: (2019)

Novel Dual Color Immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma
por: Bhalla, Ritu, et al.
Publicado: (2013)

BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer
por: Li, Xiangyi, et al.
Publicado: (2018)

Validating fPSA Glycoprofile as a Prostate Cancer Biomarker to Avoid Unnecessary Biopsies and Re-Biopsies
por: Bertok, Tomas, et al.
Publicado: (2020)

Evaluation of the PI-RADS Scoring System for Classifying mpMRI Findings in Men with Suspicion of Prostate Cancer
por: Junker, Daniel, et al.
Publicado: (2013)

Clonal Evaluation of Prostate Cancer Foci in Biopsies with Discontinuous Tumor Involvement by Dual ERG/SPINK1 Immunohistochemistry
por: Fontugne, Jacqueline, et al.
Publicado: (2016)

Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
por: Strittmatter, F, et al.
Publicado: (2011)

Interleukin 1beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells.
por: Culig, Z., et al.
Publicado: (1998)

Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa)
por: Stephan, Carsten, et al.
Publicado: (2014)

Molecular Characterization and Clinical Impact of TMPRSS2-ERG Rearrangement on Prostate Cancer: Comparison between FISH and RT-PCR
por: Fernández-Serra, A., et al.
Publicado: (2013)

Development and validation of a novel multivariate risk score to guide biopsy decision for the diagnosis of clinically significant prostate cancer
por: Klocker, Helmut, et al.
Publicado: (2020)

Expression and ERG regulation of PIM kinases in prostate cancer
por: Eerola, Sini K., et al.
Publicado: (2021)

Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA
por: Kristiansen, Ilka, et al.
Publicado: (2017)

Metastatic prostate cancer in the modern era of PSA screening
por: Fontenot, Philip A., et al.
Publicado: (2017)

Characterisation of the main PSA glycoforms in aggressive prostate cancer
por: Gratacós-Mulleras, Anna, et al.
Publicado: (2020)

Genetically adjusted PSA levels for prostate cancer screening
por: Kachuri, Linda, et al.
Publicado: (2023)

Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer
por: Cho, Hyungseok, et al.
Publicado: (2022)

SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG
por: Shoag, Jonathan, et al.
Publicado: (2017)

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification
por: Furusato, B, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_1v1qmnvbp734oqe2dvf5jpuup2